AGRX - Agile Therapeutics Inc Stock Price, Fair Value and News

$1.51

Market Closed

AGRX Stock Valuation Analysis

Valuation

Max Portfolio %

AGRX Price Action

AGRX RSI Chart

AGRX Stock Valuation Analysis

Valuation

Max Portfolio %

AGRX Valuation

AGRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AGRX Fundamentals

AGRX Revenue

AGRX Earnings

AGRX Profitability

AGRX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.5M	21.6M	0	0
2023	12.9M	16.3M	20.0M	19.6M
2022	5.7M	6.7M	8.4M	10.9M
2021	1.6M	2.5M	3.3M	4.1M
2020	0	0	0	749.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Agile Therapeutics Inc

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

CEO	Mr. Alfred F. Altomari
WEBSITE	agiletherapeutics.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	22